Cartesian Therapeutics/RNAC

$0.74

-5.74%
-
1D1W1MYTD1YMAX

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.
Ticker
RNAC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Carsten Brunn
Employees
-
Headquarters
Watertown, United States

RNAC Metrics

BasicAdvanced
$127.45M
Market cap
-
P/E ratio
-$0.24
EPS
0.60
Beta
-
Dividend rate

What the Analysts think about RNAC

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
339.19% upside
High $5.00
Low $1.00
$0.74
Current price
$3.25
Average price target

RNAC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-138.46% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$6.5M
25%
Net income
$-9M
-20.35%
Profit margin
-138.46%
-36.28%

RNAC Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.86%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.04
-$0.14
-$0.07
-$0.06
-
Expected
-$0.07
-$0.09
-$0.08
-$0.06
-$0.04
Surprise
-154.9%
60.66%
-12.5%
2.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Cartesian Therapeutics stock

Buy or sell Cartesian Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing